332 related articles for article (PubMed ID: 34681023)
41. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
Wang G; Zeng D; Sweren E; Miao Y; Chen R; Chen J; Wang J; Liao W; Hu Z; Kang S; Garza LA
J Invest Dermatol; 2023 Aug; 143(8):1579-1590.e5. PubMed ID: 36842525
[TBL] [Abstract][Full Text] [Related]
42. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
43. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
[TBL] [Abstract][Full Text] [Related]
44. Single-cell analysis of peripheral CD8
Khojandi N; Connelly L; Piening A; Hoft SG; Pherson M; Donlin MJ; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2023 Feb; 72(2):397-408. PubMed ID: 35907015
[TBL] [Abstract][Full Text] [Related]
45. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
46. Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives.
Indini A; Lombardo M; Sidoni A; Gianatti A; Mandalà M; Massi D
Adv Anat Pathol; 2023 May; 30(3):218-229. PubMed ID: 36221225
[TBL] [Abstract][Full Text] [Related]
47. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
48. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
49. Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments.
He Z; Xin Z; Yang Q; Wang C; Li M; Rao W; Du Z; Bai J; Guo Z; Ruan X; Zhang Z; Fang X; Zhao H
Elife; 2022 Jul; 11():. PubMed ID: 35894206
[TBL] [Abstract][Full Text] [Related]
50. Single-cell transcriptomics reveals a low CD8
Peng YL; Xiong LB; Zhou ZH; Ning K; Li Z; Wu ZS; Deng MH; Wei WS; Wang N; Zou XP; He ZS; Huang JW; Luo JH; Liu JY; Jia N; Cao Y; Han H; Guo SJ; Dong P; Yu CP; Zhou FJ; Zhang ZL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121646
[TBL] [Abstract][Full Text] [Related]
51. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
52. Mapping the single cell spatial immune landscapes of the melanoma microenvironment.
Magrill J; Moldoveanu D; Gu J; Lajoie M; Watson IR
Clin Exp Metastasis; 2024 Jan; ():. PubMed ID: 38217840
[TBL] [Abstract][Full Text] [Related]
53. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
[TBL] [Abstract][Full Text] [Related]
54. Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment.
Ren X; Zhang L; Zhang Y; Li Z; Siemers N; Zhang Z
Annu Rev Immunol; 2021 Apr; 39():583-609. PubMed ID: 33637019
[TBL] [Abstract][Full Text] [Related]
55. Recent advancements in tumour microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis.
Andhari MD; Antoranz A; De Smet F; Bosisio FM
Int Rev Cell Mol Biol; 2024; 382():207-237. PubMed ID: 38225104
[TBL] [Abstract][Full Text] [Related]
56. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
57. Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy.
Meng J; Huang X; Qiu Y; Zheng X; Huang J; Wen Z; Yao J
Aging (Albany NY); 2021 Nov; 13(21):24379-24401. PubMed ID: 34753832
[TBL] [Abstract][Full Text] [Related]
58. Integrative insights and clinical applications of single-cell sequencing in cancer immunotherapy.
Liu Z; Li H; Dang Q; Weng S; Duo M; Lv J; Han X
Cell Mol Life Sci; 2022 Oct; 79(11):577. PubMed ID: 36316529
[TBL] [Abstract][Full Text] [Related]
59. Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges.
Indini A; Massi D; Pirro M; Roila F; Grossi F; Sahebkar A; Glodde N; Bald T; Mandalà M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):477-490. PubMed ID: 35752398
[TBL] [Abstract][Full Text] [Related]
60. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.
Huang AC; Zappasodi R
Nat Immunol; 2022 May; 23(5):660-670. PubMed ID: 35241833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
